Abstract Number: 0227 • ACR Convergence 2024
Active Hand Inflammation: Differing Clinical and Ultrasound Patterns in Patients with Rheumatoid Arthritis and Psoriatic Arthritis. A Cross-Sectional and Multicenter Study
Background/Purpose: The ultrasound (US) finding of proliferative synovitis (PS) in Rheumatoid Arthritis (RA), is associated with ACPA, erosions and changes in therapy [1]. However, no…Abstract Number: 0588 • ACR Convergence 2024
Sex-Related Differences in Baseline Patient and Disease Characteristics: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies in Patients with Active Psoriatic Arthritis
Background/Purpose: Although PsA occurs in males and females at similar rates, clinical manifestations and outcomes differ between sexes. Findings from real-world evidence (RWE) studies have…Abstract Number: 0974 • ACR Convergence 2024
Number of Days Between Prior Low-dose Weekly Methotrexate Administration and S1-RBD Antibody Response in Adults with Immune Mediated Inflammatory Diseases Vaccinated Against COVID-19: Secondary Analysis of the Vaccine Response On-Off Methotrexate (VROOM) Study Data
Background/Purpose: Immunosuppression attenuates immune response to vaccination. A 2-week interruption in low-dose weekly methotrexate immediately after COVID-19 booster improved antibody response to vaccination. There is…Abstract Number: 1316 • ACR Convergence 2024
Dual Therapy with a JAKi and bDMARD in Patients with Standard Treatment Resistant Rheumatic Disease: A Case Series
Background/Purpose: Due to concerns about side effects, combined JAK inhibitors (JAKi) and biologic DMARDs (bDMARDs) have not been recommended for rheumatologic conditions. However, combining them…Abstract Number: 1467 • ACR Convergence 2024
Time to First Clinically Meaningful Efficacy Responses in Musculoskeletal and Patient Reported Outcomes in Patients with Active Psoriatic Arthritis Treated with Risankizumab: A Post Hoc Analysis of the Phase 3 KEEPsAKE 1 and KEEPsAKE 2 Trials
Background/Purpose: The phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized double-blind clinical trials demonstrate that risankizumab (RZB) provides a high level of durable improvement in…Abstract Number: 1904 • ACR Convergence 2024
Evaluation of the Economic Burden of Psoriatic Arthritis: Assessment of Direct Costs Using National Administrative Databases at National Level
Background/Purpose: Psoriatic arthritis (PsA) is a high-cost disease due to its significant impact on patients' quality of life and the extensive resources required for its…Abstract Number: 2316 • ACR Convergence 2024
Gene Expression Profile Is Different Between Men and Women in Psoriatic Disease
Background/Purpose: Psoriatic arthritis (PsA) is a highly heterogenous chronic inflammatory condition. Recent publications highlight differences between men and women in disease manifestation and response to…Abstract Number: 2333 • ACR Convergence 2024
Unveiling New Molecular Signatures in Psoriatic Arthritis Using Comprehensive Proteomic Analysis of Peripheral Mononuclear Cells
Background/Purpose: Diagnosing psoriatic arthritis (PsA) is challenging, underscoring the importance of discovering novel biomarkers through proteomics for early and accurate detection. Molecular clustering can elucidate…Abstract Number: 2354 • ACR Convergence 2024
Predictors of Clinical Response to Intravenous Secukinumab Among Patients with PsA: A Post Hoc Analysis of a Phase 3 Trial
Background/Purpose: To assess baseline demographics and clinical characteristics of patients with PsA that are most associated with achievement of clinical response to intravenous (IV) secukinumab…Abstract Number: 2586 • ACR Convergence 2024
Results from the Biopsy Driven Ebio Study: Entheseal Tissue Signature in Response to IL-17 Blockade in Psoriatic Arthritis
Background/Purpose: Enthesitis is considered to be an early event in psoriatic arthritis (PsA) course, representing a hallmark feature of the disease. So far, most of…Abstract Number: 0067 • ACR Convergence 2024
Psoriasis Patients at Risk for Psoriatic Arthritis Have Increased Levels of Circulating Pro-migratory Dendritic Cells
Background/Purpose: Early diagnosis of Psoriatic Arthritis (PsA) is critical for timely intervention to prevent poor clinical outcomes. Despite well-known clinical predictors of PsA, the mechanisms…Abstract Number: 0231 • ACR Convergence 2024
Imaging Characteristics and Demographic Variations in Patients with Axial Spondylarthritis, Axial Psoriatic Arthritis, and Inflammatory Bowel Disease-Related Arthritis with Axial Involvement: Insights from a Single Center at Cleveland Clinic Abu Dhabi
Background/Purpose: Spondyloarthropathies (SpAs) are a group of seronegative, inflammatory arthritides, including axial spondylarthritis (ax-SpA), axial psoriatic arthritis (ax-PsA), and inflammatory bowel disease related arthritis with…Abstract Number: 0589 • ACR Convergence 2024
Time to Clinical Response to Secukinumab Across Disease Domains Among Patients with Psoriatic Arthritis: A Pooled Post Hoc Analysis of 4 Phase 3 Trials
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory disease that can manifest with considerable clinical heterogeneity. Secukinumab demonstrated improvements across the updated Group for Research and…Abstract Number: 1006 • ACR Convergence 2024
Associations Between Rheumatic Diseases and Mental Health Disorders
Background/Purpose: Rheumatic diseases are frequently linked to a reduced quality of life (QoL), particularly as disease severity escalates. Patients with rheumatic conditions often exhibit high…Abstract Number: 1389 • ACR Convergence 2024
Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter
Background/Purpose: Since the compound patent on the bio-originator of adalimumab expired, several adalimumab biosimilars (BS) have been introduced. Extensive research shows equivalence in effectiveness and…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 81
- Next Page »